Radioiodide (RAI) therapy of thyroid cancer exploits the relatively selective ability of thyroid cells to transport and accumulate iodide. Iodide uptake requires expression of critical genes that are involved in various steps of thyroid hormone biosynthesis. ERK signaling, which is markedly increased in thyroid cancer cells driven by oncogenic \textit{BRAF}, represses the genetic program that enables iodide transport. Here, we determined that a critical threshold for inhibition of MAPK signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with \textit{Braf}^{V600E}-induced thyroid cancer. Although the MEK inhibitor selumetinib transiently inhibited ERK signaling, which subsequently rebounded, the MEK inhibitor CKI suppressed ERK signaling in a sustained manner by preventing RAF reactivation. A small increase in ERK inhibition markedly increased the expression of thyroid differentiation genes, increased iodide accumulation in cancer cells, and thereby improved responses to RAI therapy. Only a short exposure to the drug was necessary to obtain a maximal response to RAI. These data suggest that potent inhibition of ERK signaling is required to adequately induce iodide uptake and indicate that this is a promising strategy for the treatment of \textit{BRAF}-mutant thyroid cancer.
Sustained ERK inhibition maximizes responses of \textit{Braf}^{V600E} thyroid cancers to radioiodine

James Nagarajah,1,2 Mina Le,1,3 Jeffrey A. Knauf,1 Giuseppe Ferrandino,4 Cristina Montero-Conde,1 Nagavarakishore Pillarsetty,5 Alexander Bolaender,3 Christopher Irwin,2 Gnana Prakash Krishnamoorthy,1 Mahesh Saqena,1 Steven M. Larson,2,5 Alan L. Ho,6 Venkatraman Seshan,7 Nobuya Ishii,8 Nancy Carrasco,4 Neal Rosen,5,6 Wolfgang A. Weber,2,5 and James A. Fagin1,6

1Human Oncology and Pathogenesis Program, 2Molecular Imaging and Therapy Service, and 3Department of Surgery, Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical College, New York, New York, USA. 4Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, Connecticut, USA. 5Molecular Pharmacology and Chemistry Program, 6Department of Medicine, 7Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical College, New York, New York, USA. 8Discovery Pharmacology Department, Chugai Pharmaceutical Company, Tokyo, Japan.

Radioiodide (RAI) therapy of thyroid cancer exploits the relatively selective ability of thyroid cells to transport and accumulate iodide. Iodide uptake requires expression of critical genes that are involved in various steps of thyroid hormone biosynthesis. ERK signaling, which is markedly increased in thyroid cancer cells driven by oncogenic \textit{BRAF}, represses the genetic program that enables iodide transport. Here, we determined that a critical threshold for inhibition of MAPK signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with \textit{Braf}^{V600E}-induced thyroid cancer. Although the MEK inhibitor selumetinib transiently inhibited ERK signaling, which subsequently rebounded, the MEK inhibitor CKI suppressed ERK signaling in a sustained manner by preventing RAF reactivation. A small increase in ERK inhibition markedly increased the expression of thyroid differentiation genes, increased iodide accumulation in cancer cells, and thereby improved responses to RAI therapy. Only a short exposure to the drug was necessary to obtain a maximal response to RAI. These data suggest that potent inhibition of ERK signaling is required to adequately induce iodide uptake and indicate that this is a promising strategy for the treatment of \textit{BRAF}-mutant thyroid cancer.

Introduction

Effective radioiodide (RAI) therapy of metastatic thyroid cancers requires uptake of RAI via the sodium/iodide symporter (NIS), and optimally, its incorporation into tyrosine residues of thyroglobulin (TG) to increase the residence time of the isotope. Unfortunately, many metastatic tumors do not trap iodide efficiently, which is associated with worse prognosis (1). Papillary thyroid cancers (PTCs) harbor mutually exclusive mutations of oncogenes encoding activators of MAPK signaling (i.e., \textit{RET}, \textit{NTRK}, \textit{RAS}, and \textit{BRAF}) (2). Oncogenic activation of MAPK in thyroid cells leads to loss of expression of genes required for thyroid hormone biosynthesis, including NIS, thyroid peroxidase (TPO), and TG (3–5).

The \textit{Braf}^{V600E} mutation is the most frequent alteration in PTC, and is associated with worse outcomes. \textit{BRAF}-mutant cancers have lower expression of NIS, TPO, and TG than those with wild-type (WT) \textit{BRAF} (6), and are particularly refractory to RAI therapy (7). Mice with doxycycline (dox)-inducible \textit{Braf}^{V600E} in thyroid cells develop PTCs that fail to incorporate RAI, which is restored when \textit{Braf}^{V600E} expression is switched off by dox withdrawal, or by treatment with BRAF inhibitors or with the allosteric MEK1/2 inhibitor AZD6244 (selumetinib) (8).

Consistent with this, selumetinib activated iodide uptake at metastatic sites in most patients with RAI-refractory metastatic thyroid cancer, and resulted in remarkable clinical responses. Therapeutic benefit was striking in patients with \textit{RAS}-mutant tumors, but much less so in those with \textit{BRAF}-mutant tumors (9).

RAF and MEK inhibitors are comparatively ineffective suppressors of \textit{Braf}^{V600E}-driven signaling and growth in thyroid cancer cells. Their initial potent inhibition of ERK signaling is followed by a marked rebound to levels approaching those in untreated cells. This is due to relief of ERK-dependent feedback inhibition of the pathway, increased receptor tyrosine kinase (RTK) expression (especially HER3), and activation of RTK signaling via RAS and CRAF (RAF1) (10, 11). Binding of MEK to inhibitors causes it to bind to the reactivated CRAF kinase. In the complex, MEK is phosphorylated, activated, and released. This attenuates pathway inhibition by most MEK inhibitors. CHS126766 (CKI) is an allosteric MEK inhibitor that, by binding to the protein, causes it to adopt a conformation in which it cannot be phosphorylated by RAF. The drug-bound MEK functions as a dominant-negative inhibitor of WT and activated mutant RAF kinases and reduces feedback reactivation of ERK signaling (12, 13).

Here we investigated whether a more profound and sustained inhibition of MAPK signaling in mice with \textit{Braf}^{V600E}-induced PTC can be attained with CKI, and whether this would result in greater restoration of expression of thyroid differentiation genes, increased iodide accumulation, and response to RAI therapy.
Results and Discussion

Full restoration of NIS in thyroid PCCL3 cells expressing BRAFV600E requires profound inhibition of MAPK signaling. We expressed BRAFV600E in a dox-dependent manner in PCCL3 cells, which profoundly suppresses NIS (Figure 1A), and used this system to examine the effects of pharmacological inhibition of ERK signaling. Cells expressing BRAFV600E were incubated with the indicated concentrations of the RAF inhibitor PLX4032, the MEK inhibitor U0126, alone or in combination. ERK phosphorylation was used as readout of MAPK pathway activity. We found a strong negative correlation between phospho-ERK (p-ERK) and NIS, irrespective of the compound(s) used to inhibit the pathway (Figure 1, A and B). However, the relationship between p-ERK and NIS was nonlinear, and NIS levels were fully restored only when p-ERK was suppressed to or below baseline (no dox) levels. This observation was replicated using the MEK inhibitors AZD6244 and CKI (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI89067DS1).

CKI induces a more sustained inhibition of MAPK signaling than AZD6244 in PTC expressing endogenous levels of BrafV600E. We next explored the pharmacodynamic effects of the MEK inhibitors CKI and AZD6244 on MAPK signaling in thyroid cancers of TPO-Cre LSL-BrafV600E mice, which develop full penetrance of PTCs by 5 weeks (14). AZD6244 profoundly inhibited p-ERK at 2 hours, fol-
Modest additional decrements in MAPK transcriptional output evoke major increases in expression of iodide-metabolizing genes in Braf<sup>V600E</sup>-induced PTCs. Levels of p-ERK are relatively crude indicators of MAPK pathway activity, which is better assessed by measuring key transcripts regulated by ERK (16). Fosl1 and Dusp5 mRNA levels, which are sensitive MAPK biomarkers in thyroid cancer cells (10), are low in WT thyroid, and markedly increased in Braf<sup>V600E</sup>-induced PTCs. Treatment with AZD6244 inhibited their expression by ~70%, as did low-dose CKI (0.38 mg/kg/d), whereas 1.5 mg/kg/d CKI did so by 85% (Figure 1F). This modest additional decrease in ERK output resulted in remarkable differential effects on thyroid differentiated gene expression, with CKI (1.5 mg/kg/d) showing far greater potency in increasing their expression: NIS, 16% vs. 82%; Tshr, 73% vs. 31%; Tg, 5% vs. 36% of WT thyroid levels for AZD6244 and CKI, respectively (Figure 1G). The expression of these genes in mice treated with low-dose CKI was comparable to AZD6244. Thus, expression of genes required for iodide transport is reciprocal and exquisitely sensitive to MAPK pathway activity.

Kinetics of NIS activity in Braf<sup>V600E</sup>-induced PTCs as determined by <sup>18</sup>F-tetrafluoroborate (TFB) scanning. Iodine isotopes are not of value to determine the time course of iodine incorporation in vivo during treatment with MAPK pathway inhibitors because of their long half-life. <sup>18</sup>F-TFB is also transported by NIS and has a physical half-life of 110 minutes (17). We confirmed these properties in rat IEC6

Figure 2. <sup>18</sup>F-TFB uptake and kinetic analysis in IEC6 intestinal rat cells and in TPO-Cre LSL-Braf<sup>V600E</sup> mouse PTCs in response to MAPK inhibitors. (A) Rates of TFB uptake (2-minute time points) were determined at 140 mM Na<sup>+</sup> with various concentrations of TFB. The K<sub>m</sub> and V<sub>max</sub> were 9.4 ± 1.1 μM and 17 ± 1.1 pmol/μg DNA/2 min, respectively. (B) <sup>18</sup>F-TFB uptake in IEC6 cells in the absence or presence of ClO<sub>4</sub><sup>-</sup> or sodium (mean ± SD). (C) Fluorine is not transported via NIS. (D) Time course of <sup>18</sup>F-TFB uptake by PET of PTCs of TPO-Cre LSL-Braf<sup>V600E</sup> mice treated with vehicle (n = 5), AZD6244 (50 mg/kg twice per day, n = 5) or CKI (1.5 mg/kg once per day, n = 5) for 21 days. Graph shows thyroid uptake of <sup>18</sup>F-TFB normalized for tumor volume given in % uptake of injected activity (*P = 0.008, CKI vs. AZD6244). Upper row shows representative axial PET thyroid images of mice treated with CKI (magnification ×2.5). Serum TSH was markedly increased in TPO-Cre LSL-Braf<sup>V600E</sup> compared with wild-type mice, as these animals become hypothyroid upon Braf<sup>V600E</sup> expression, and were not significantly different in vehicle- vs. CKI/AZD6244-treated animals (not shown). Hence, all <sup>18</sup>F-TFB uptake experiments were performed under TSH-stimulated conditions.
pled to the Na⁺ electrochemical gradient generated by the Na⁺/K⁺ ATPase (Figure 2, A–C). Using serial PET imaging with ¹⁸F-TFB we show that peak ¹⁸F-TFB uptake occurred 8–12 days after treatment with AZD6244 or CKI, and that CKI-treated mice had markedly

intestinal epithelial cells, which endogenously express more NIS than thyroid-derived FRTL5 cells (18). IEC6 cells do not transport ¹⁸F-TFB in the absence of Na⁺, and ¹⁸F-TFB accumulation is inhibited by perchlorate, indicating that NIS transport of ¹⁸F-TFB is cou-

Figure 3. Profound MAPK pathway blockade with CKI maximizes ¹²⁴I uptake and response to RAI therapy in Braf-induced PTCs. (A) Protocol to explore effects of MAPK pathway inhibitors on ¹²⁴I incorporation in TPO-Cre LSL-BrafV600E mice. (B and C) Thyroid uptake of ¹²⁴I normalized for tumor volume was used to calculate: (B) maximum uptake of ¹²⁴I and (C) predicted lesional radiation dose if given 1 mCi (37 MBq) of ¹³¹I. **P = 0.0043, *P = 0.017, Mann-Whitney test. (D) Tumor volume measured by ultrasound at time 0 (4.5 days after treatment with vehicle, AZD6244, or CKI, and prior to administration of ¹³¹I), and at the indicated times after RAI therapy. The green line shows PTC volume in age-matched untreated mice. Five mice per group were treated with the indicated drugs. Two mice of the vehicle group died after 12 weeks. Volume differences in all groups were statistically significant (at 24 weeks: ****P < 0.0001 by Kruskal-Wallis test; **P = 0.008 for AZD6244 vs. CKI by Mann-Whitney test). (E–G) Histology of PTCs of TPO-Cre LSL-BrafV600E mice at 24 weeks. Scale bars: 1,000 μm. (E) H&E, (F and G) IHC for pan-cytokeratin (F) or p-ERK (G) of representative sections from untreated mice, or mice treated with vehicle + ¹³¹I, AZD6244 + ¹³¹I, or CKI + ¹³¹I. Black arrows point to vestigial remains of PTC in thyroid lobes after CKI + ¹³¹I.
higher uptake throughout the time course (Figure 2D). Prolonged treatment for up to 22 days was not associated with greater iodide accumulation with either compound (Supplemental Figure 3).

**CKI induces higher iodine-124 uptake than AZD6244.** We next determined the effects of AZD6244 and CKI on iodide accumulation in BraFV600E-induced murine PTCs. Based on the kinetics of 124I-PET uptake we performed. 124I-PET thyroid dosimetry before and 8 days after treatment with each drug (Figure 3A). Both drugs increased 124I uptake, although CKI treatment had a -2-fold greater effect than AZD6244 (Figure 3, B and C).

**CKI, and to a lesser extent AZD6244, markedly enhances responses to RAI therapy.** Lesional dosimetry of thyroid tumors from mice pre-treated with AZD6244 or CKI prior to RAI administration revealed a higher tumor dose (Figure 3C), and, accordingly, showed significant reduction in tumor size compared with mice given RAI alone (Figure 3D). CKI showed the greatest effectiveness, as almost no measurable remnant of the thyroid was present 24 weeks after RAI therapy. Thus, only vestigial pockets of epithelial cells remained surrounded by areas of dense fibrosis in the mice pretreated with the CKI, whereas in those treated with AZD6244 there was persistent PTC (Figure 3, E–G and Supplemental Figure 4).

Human PTCs have a very low overall somatic mutation burden (19). As a consequence of their genomic simplicity, the key oncogenic drivers of the disease are associated with clearly discernible biological, signaling, and gene expression properties. The TCGA study of PTCs showed distinct differences between tumors with **BRAF**-mutant cancers (16). This is explainable in part because ERK-dependent inhibitory phosphorylation of CRAF attenuates pathway output in RTK- and RAS-mutant cells (20). As **BRAF**V600E signals as a monomer, it is unresponsive to this constraint, resulting in a greater flux through the pathway (21). Inhibition of mutant **BRAF** in thyroid cancer cells poses unique challenges, as reactivation of MAPK signaling by release of these negative feedbacks is particularly robust in this lineage (10). We show here that therapeutically relevant restoration of iodide accumulation into **BRAF**-mutant thyroid cancers can be attained by combined RAF-MEK kinase blockade, as this suppresses pathway output beyond the 70% that can be obtained by the MEK inhibitor selumetinib alone.

The clinical efficacy of vemurafenib in patients with **BRAF**-mutant melanoma was found to be greatest in patients who had a deep reduction of ERK phosphorylation in the tumor cells (by at least 80%) (22). We found that a reduction of expression of MAPK transcriptional output markers from 70% (with selumetinib or low-dose CKI) to 85% (with high-dose CKI) had profound reciprocal effects on the expression of **NIS**, **Tg**, and **Tshr**. This shows that potent ERK inhibition is required for treating these tumors effectively, and has implications for other cancers that depend on this pathway for viability.

Toxicity of achieving high-level ERK pathway inhibition can be a constraint on these approaches. For this application we show that treatment for as little as 8 days is sufficient to enable effective RAI therapy. We show that 18F-TFB is a promising tool to perform quantitative lesional analysis and identify patients likely to benefit from RAI therapy (23), because it is transported by NIS, has a short half-life, and can be given repeatedly to determine the optimal time to administer a therapeutic dose of RAI.

Monotherapy with either selumetinib (9) or the RAF inhibitor dabrafenib (24) increases iodide accumulation in a significant fraction of patients with metastatic **BRAF**-thyroid cancers, but is insufficient to induce major clinical responses to RAI in most of them. We show that treatment with a MEK inhibitor that prevents RAF reactivation of ERK signaling overcomes the adaptive responses to these agents and markedly enhances the effectiveness of the approach. This reinforces the critical significance of profound inhibition of the MAPK transcriptional output to maximize responses to RAI therapy, and will guide future development of this treatment strategy.

### Methods

**Statistics.** P values were calculated using a 2-sided Mann-Whitney test, Wilcoxon signed-rank test, or Kruskal-Wallis test as indicated in the legends. A P value of < 0.05 was considered significant. All data were reported as the mean ± SEM unless otherwise indicated.

**Study approval.** All studies were approved by the IACUC of Memorial Sloan Kettering Cancer Center.

**Author contributions**

JAF, JAK, and JN designed the study. JN, ML, GF, NP, AB, CI, GPK, and MS conducted the experiments. JN, AH, SL, NI, NC, and JAF analyzed the data. JAF, JN, NC, WW, and NR wrote the manuscript.

**Acknowledgments**

This work was supported by NIH grants CA50706, CA72597, P50CA72012, and P30CA08748, the Society of Memorial Sloan Kettering, the Byrne fund, the David Linn Family fund, and the German Research Foundation (DFG, NA 1133/1-1). We thank Philip Blower, Department of Imaging Chemistry, Kings College, London, for the protocol for TFB synthesis, Walter Jentzen, University Hospital of Duisburg-Essen, Germany, for support in the analysis of the 18F-PET dosimetry, and the Molecular Cytology, Comparative Pathology, and Animal Imaging Core Facilities of the Sloan Kettering Institute.

Address correspondence to: James Fagin or Wolfgang Weber or Neal Rosen, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA. Phone: 646.888.2136; E-mail: faginj@mskcc.org (J. Fagin). Phone: 212.639.7373; E-mail: weberw@mskcc.org (W. Weber). Phone: 646.888.2075; E-mail: rosenm@mskcc.org (N. Rosen).


